Conexeu Sciences (NASDAQ:CNXU) Posts Quarterly Earnings Results, Misses Estimates By $0.19 EPS

Key Points

• Conexeu Sciences reported quarterly EPS of -$0.29, missing the consensus estimate of -$0.10 by $0.19.
• Shares rose to $5.00 during Monday trading, but remain well below the 50-day moving average of $8.09 and the 52-week high of $18.79.
• Analyst sentiment is mixed, with ratings ranging from buy to sell and an overall “Hold” consensus; meanwhile, director Lynn Sebastian Purcell purchased 202,500 shares at $0.80 each.

Conexeu Sciences (NASDAQ:CNXU - Get Free Report) released its earnings results on Monday. The company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.19), Zacks reports.

Conexeu Sciences Price Performance

Conexeu Sciences stock traded up $0.54 during mid-day trading on Monday, hitting $5.00. 189,629 shares of the company were exchanged, compared to its average volume of 157,771. The company has a market capitalization of $133.80 million and a P/E ratio of -45.45. The business has a fifty day moving average of $8.09. Conexeu Sciences has a 1-year low of $4.19 and a 1-year high of $18.79.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on CNXU shares. Wall Street Zen raised Conexeu Sciences to a "hold" rating in a research note on Saturday, May 30th. Zacks Research raised shares of Conexeu Sciences to a "hold" rating in a research note on Monday, June 29th. Weiss Ratings assumed coverage on shares of Conexeu Sciences in a report on Monday, August 17th. They set a "sell (e-)" rating on the stock. Finally, HC Wainwright assumed coverage on shares of Conexeu Sciences in a research note on Monday, June 22nd. They issued a "buy" rating and a $20.00 price objective for the company. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $20.00.

Insider Buying and Selling at Conexeu Sciences

In other news, Director Lynn Sebastian Purcell bought 202,500 shares of the stock in a transaction dated Thursday, June 18th. The stock was bought at an average cost of $0.80 per share, with a total value of $162,000.00. Following the purchase, the director owned 2,734,240 shares of the company's stock, valued at approximately $2,187,392. This represents a 8.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website.

Conexeu Sciences Company Profile

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. --- Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property ("IP") developed over more than a decade at the University of British Columbia (the "University") and the BC Professional Firefighters Burn and Wound Healing Laboratory.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.